Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1432-2161
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT ; day:7 ; month:8 ; year:2021 ; pages:1-22
Skeletal radiology ; (7.8.2021), 1-22

Creator
Lecouvet, Frederic E.
Vekemans, Marie-Christiane
Van Den Berghe, Thomas
Verstraete, Koenraad
Kirchgesner, Thomas
Acid, Souad
Malghem, Jacques
Wuts, Joris
Hillengass, Jens
Vandecaveye, Vincent
Jamar, François
Gheysens, Olivier
Vande Berg, Bruno C.
Contributor
SpringerLink (Online service)

DOI
10.1007/s00256-021-03841-5
URN
urn:nbn:de:101:1-2021103022482891064481
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:36 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Lecouvet, Frederic E.
  • Vekemans, Marie-Christiane
  • Van Den Berghe, Thomas
  • Verstraete, Koenraad
  • Kirchgesner, Thomas
  • Acid, Souad
  • Malghem, Jacques
  • Wuts, Joris
  • Hillengass, Jens
  • Vandecaveye, Vincent
  • Jamar, François
  • Gheysens, Olivier
  • Vande Berg, Bruno C.
  • SpringerLink (Online service)

Other Objects (12)

Minimal residual disease in multiple myeloma: current status

Minimal residual disease in multiple myeloma: current status

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment

Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions

Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions

Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum

Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum

Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma

Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma

Minimal residual disease: premises before promises

Minimal residual disease: premises before promises

The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma

The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma

Minimal Residual Disease in Acute Lymphoblastic Leukemia

Minimal Residual Disease in Acute Lymphoblastic Leukemia

Radiomics analysis of bone marrow biopsy locations in [18F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma

Radiomics analysis of bone marrow biopsy locations in [18F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma

High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes

High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes

Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma

Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Related objects